

## **The pre-launch phase of SCIZYS by Lumito continues without interruption**

The pre-launch phase, which started in Spring 2022, continues and is now intensified as planned. Lumito will be represented with its own stand at the Digital Pathology & AI Congress: Europe in London on December 7-8. The presence at the congress will be complemented by advertising and editorial in the international professional journal *The Pathologist* during October-December. In addition, many marketing activities are underway, including a digital campaign on LinkedIn to reach more researchers, pathologists, and oncologists in Sweden as well as in the rest of the Nordic region during November-December. All to reach the intended target group in the prioritized and planned geographic market.

- Strengthened by the great interest the market showed in our product solution at the European Congress of Pathology in Basel, we are planning participation in the next major congress, Digital Pathology & AI Congress: Europe. At the same time, follow-up work continues regarding the international contacts established in Basel. We have also renewed contact with the potential partners, research groups and research laboratories that we have been in contact with previously, says Mattias Lundin, Lumito's CEO.

The ambition is to be ready and have the first customers defined when SCIZYS enters the sharp launch phase, is CE marked and available, even if the launch has been slightly delayed as announced earlier.

### **For further information, please contact:**

Lumito's CEO, Mattias Lundin  
e-mail: [ml@lumito.se](mailto:ml@lumito.se)  
Tel: +46 76 868 45 09  
[www.lumito.se](http://www.lumito.se)

## PRESS RELEASE

2022-11-01



**Lumito** specializes in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalized healthcare. The technology enables higher contrast images without irrelevant background information, making it easier for pathologists to find cancer indications. The technology, based on Up Converting NanoParticles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shortened analysis times. The method has several potential applications, but Lumito has chosen to focus primarily on digital pathology and first on a release of SCIZYS by Lumito for use in research laboratories. The company is a spin-off from a research group at the Department of Atomic Physics and Laser Centre. [www.lumito.se/en](http://www.lumito.se/en)

The share is traded on NGM Nordic SME, under the name LUMITO and Mentor is Mangold Fondkommission, phone: 08-503 015 50.